EFFECT OF CHOLECALCIFEROL AND ITS COMBINATION WITH METFORMIN ON THE LIPID AND CARBOHYDRATE STATUS IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME

Authors

  • Arkhypkina T. L. SI “V. Danilevsky Institute for Endocrine Pathology Problems of the National Academy of Medical Science of Ukraine”, Kharkiv, Ukraine https://orcid.org/0000-0001-5529-7583
  • Bondarenko V. A. SI “V. Danilevsky Institute for Endocrine Pathology Problems of the National Academy of Medical Science of Ukraine”, Kharkiv, Ukraine; Kharkiv Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine, Ukraine https://orcid.org/0000-0002-9254-3875
  • Lyubimovа L. P. SI “V. Danilevsky Institute for Endocrine Pathology Problems of the National Academy of Medical Science of Ukraine”, Kharkiv, Ukraine https://orcid.org/0000-0003-2984-6969

DOI:

https://doi.org/10.21856/j-PEP.2022.1.01

Keywords:

polycystic ovary syndrome, vitamin D, dyslipidemia, insulin resistance

Abstract

Objective. To investigate the effect of therapy with cholecalciferol, metformin and their combination to indicator of carbohydrate and lipid metabolism in women with polycystic ovary syndrome (PCOS) and insulin resistance (IR).

Materials and methods. 60 women with PCOS and IR, 30 healthy women similar in age and body weight were examined. Patients were divided into 3 groups: 20 women receiving cholecalciferol at 4000 IU daily; 20 women receiving metformin at 850 mg twice a day; 20 patients taking metformin at 850 mg twice a day and cholecalciferol at 4000 IU daily. Vitamin D, glucose, immunoreactive insulin (IRI), HOMA-IR index, total cholesterol, triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), oral glucose tolerance test before and after 12 weeks of therapy were determined.

Results. Therapy with cholecalciferol was accompanied by increasing (P < 0.001) in concentrations of vitamin D (158.9 ± 4.7)%, reducing the levels of IRI (P < 0.02), the HOMA-IR indexes (P < 0.001), total cholesterol (P < 0.01) and LDL (P < 0.05), but did not had a significant effect on anthropometric parameters, glucose, TG, and HDL levels. Therapy with metformin was accompanied by decreasing body mass index (BMI) (P < 0.01), basal levels of IRI (24.6 ± 0.4)% (P < 0.001), HOMA-IR index (27.9 ± 0.4)% (P < 0.001), glycemic responses to an oral glucose load (P < 0.001), TG (P < 0.02) and increasing levels of HDL (P < 0.05). No negative dynamics of vitamin D levels was observed. Combination therapy was accompanied by increasing in concentration of vitamin D (P < 0.001), significant decreasing of BMI (P < 0.001), waist-to-hip ratio (P < 0.05), glycemic responses to an oral glucose load (P < 0.001), levels of IRI (P < 0.001) and HOMA-IR indexes (P < 0.001), more significant decreasing in total cholesterol (P < 0.001), TG (P < 0.001), LDL (P < 0.001) and increasing in HDL (P < 0.001).

Conclusion. It is expedient to use a combination of cholecalciferol with metformin in the complex of therapeutic measures aimed at the correction of metabolic disorders in women with PCOS.

References

Aversa A, La Vignera S, Rago R, et al. Front Endocrinol (Lausanne) 2020;11: 516. https://doi.org/10.3389/fendo.2020.00516.

Kalugina, LV, Tatarchuk TF. Reproductive Endocrinolog 2020;52: 54-60. https://doi.org/10.18370/2309-4117.2020.52.54-60

Caserta D, Adducchio G, Picchia S, et al. Gynecol Endocrinol 2014;30(6): 347-402. https://doi.org/10.3109/09513590.2014.887673.

Shorakae S, Ranasinha S, Abell S, et al. Clin Endocrinol (Oxf) 2018;89(5): 628-633. https://doi.org/10.1111/cen.13808.

Christ JP, Vanden Brink H, Brooks ED, et al. Fertil Steril 2015;103(3): 787-794. https://doi.org/10.1016/j.fertnstert.2014.12.094

Ito-Yamaguchi A, Suganuma R, Kumagami A, et al. Gynecol Endocrinol 2015;31(1): 44-47. https://doi.org/10.3109/09513590.2014.951321.

Palomba S, Falbo A, Russo T, et al. Hum Reprod 2010;25(4): 1005-1013. https://doi.org/10.1093/humrep/dep466.

Morley LC, Tang T, Yasmin E, et al. Cochrane Database Syst Rev 2017;11(11): D003053. https://doi.org/10.1002/14651858.CD003053.pub6.

Henríquez MS, De Tejada Romero MJG. Nutrients 2020;12(6): 1617. https://doi.org/10.3390/nu12061617.

Wang L, Shulan L, Fen L, et al. Front Endocrinol 2020;11: 171. https://doi.org/10.3389/fendo.2020.00171.

Migliaccio S, Di Nisio A, Mele C, et al. Int J Obes Supp 2019;9: 20-31. https://doi.org/10.1038/s41367-019-0010-8.

Chagas CE, Borges MC, Martini LA, Rogero MM. Nutrients 2012;4(1): 52-67. https://doi.org/10.3390/nu4010052.

Maestro B, Dávila N, Carranza MC, Calle C. J Steroid Biochem Mol Biol 2003;84(2-3): 223-230. https://doi.org/10.1016/s0960-0760(03)00032-3.

Kamycheva E, Jorde R, Figenschau Y, Haug E. J Endocrinol Invest 2007;30(2): 126-32. https://doi.org/10.1007/BF03347410.

Szymczak-Pajor I, Drzewoski J, Śliwińska A. Int J Mol Sci 2020;21(18): 6644. https://doi.org/10.3390/ijms21186644.

Han YY, Hsu SHJ, Su TC. Biomedicines 2021;9(5): 464. https://doi.org/10.3390/biomedicines9050464

Li S, He Y, Lin S, et al. Mol Nutr Food Res 2016;60(4): 798-809. https://doi.org/10.1002/mnfr.201500425.

Larrick BM, Kim KH, Donkin SS, Teegarden D. Nutr Res 2018;58: 72-83. https://doi.org/10.1016/j.nutres.2018.07.004.

Cho HJ, Kang HC, Choi SA, et al. Biol Pharm Bull 2005;28(8): 1418-23. https://doi.org/10.1248/bpb.28.1418.

Orten-Luiten ACB, Janse A, Dhonukshe-Rutten RAM, Witkamp RF. Eur J Clin Pharmacol 2016;72: 605-614. https://doi.org/10.1007/s00228-016-2016-2.

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Hum Reprod 2004;19(1): 41-47. https://doi.org/10.1093/humrep/deh098.

Manuhin IB, Gevorkyan MA, Chagay NB. Anovulyatsiya i insulinorezistentnost, Moscow, 2006: 416 p.

Rothen JP, Rutishauser J, Walter PN, et al. Sci Rep 2021;11: 18746. https://doi.org/10.1038/s41598-021-97417-x.

Jin B, Qian L, Fu X, et al. J Int Med Res 2020;48(8): 300060520935313. https://doi.org/10.1177/0300060520935313

Safi A, Orazov M, Kalinchenko S. Womens Health (Lond) 2020;16: 1-6. https://doi.org/10.1177/1745506520969606.

Out M, Top WMC, Lehert P, et al. Diab Obes Metab 2018;20(8): 1951-1956. https://doi.org/10.1111/dom.13327.

Downloads

Published

2022-03-15

How to Cite

Arkhypkina, T., Bondarenko, V., & Lyubimovа L. (2022). EFFECT OF CHOLECALCIFEROL AND ITS COMBINATION WITH METFORMIN ON THE LIPID AND CARBOHYDRATE STATUS IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME. Problems of Endocrine Pathology, 79(1), 7-14. https://doi.org/10.21856/j-PEP.2022.1.01

Issue

Section

CLINICAL ENDOCRINOLOGY